| Name | Title | Contact Details |
|---|---|---|
Kimberly Evans |
Assistant General Counsel | Profile |
Nodality is an innovative personalized medicine company focused on improving the efficiency of drug development for therapeutics as well as generating highly predictive companion diagnostics to improve patient care.
Built by science, driven by compassion. Aspenti Health is an innovative, comprehensive clinical drug testing lab that is seeking to redefine the role of the traditional healthcare testing partners. Led by experienced healthcare professionals, we are focused on shaping a future in which we are instrumental in helping our patients meet their recovery goals. We also are investing in our social mission to create lasting and effective impact through community involvement. We believe in improving patient outcomes through enhanced treatment access and patient advocacy. Unlike other testing partners, Aspenti works hand in hand with our care providers in order to better serve our mutual patient through patient-focused services such as mobile testing, data driven digital health integration, thought leadership, and strategic partnerships with leading healthcare and research institutions. It is our vision to enrich every life through diagnostic science and compassionate care.
Cellanyx has developed proprietary live tumor cell phenotypic biomarker tests to improve cancer risk-stratification and allow informed clinical decision making. The Companys unique approach provides quantitative and actionable information based on analysis of thousands of live tumor cells. The Companys tests employ a microfluidic platform combined with machine vision and machine learning approaches to analyze phenotypic morphological, biochemical and biophysical markers. Cellanyx has demonstrated initial clinical proof-of-concept with its lead phenotypic test in prostate cancer. The initial clinical proof-of-concept study was conducted to demonstrate improved risk stratification in men with low and intermediate Gleason grade (6 and 7) disease and reduce the number of repeat biopsies. Furthermore, analysis of field samples (away from the suspicious core) demonstrated the potential value of Cellanyx phenotypic test as it was able to analyze the tumor microenvironment conditions and predict expected adverse pathology from samples that were not taken from the suspicious core. These new findings from the Cellanyx prostate test are transformative as it will reduce the errors in diagnosing cancers early due to sampling heterogeneity of prostate biopsies.
We are committed to the people of our community, to help them overcome challenges and reach their greatest potential by providing quality care, people-oriented services and comfort.
BERG is a Boston-based biopharma company focused on taking a bold “back to biology” approach to therapeutic discovery using its unique AI-based Interrogative Biology® platform. This platform combines patient biology and AI-based analytics to engage the differences between healthy and disease environments. The patient’s own biology drives the platform’s results and guides us in the discovery and development of drugs, diagnostics and healthcare applications. Our platform utilizes patient population health data to bring actionable Patient IntelligenceTM to precision medicine applications. For patients this means faster discovery and development of treatments, more effective precision treatments for individuals as well as a reduction in costs to our healthcare systems. BERG has a robust product portfolio in oncology, endocrinology and neurology with mature assets in oncology entering mid and late stage trials. BERG is committed to improving the lives of patients through precision medicine made possible by our innovative platforms.